Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

zoligratinib (Debio 1347)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Debiopharm

Drug class:

FGFR inhibitor

Related drugs:

FGFR3-TACC3 fusion	Gallbladder Cancer	FGFR3-TACC3 fusion	Gallbladder Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR1 fusion	Solid Tumor	FGFR1 fusion	Solid Tumor	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 fusion	Solid Tumor	FGFR2 fusion	Solid Tumor	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR3 fusion	Solid Tumor	FGFR3 fusion	Solid Tumor	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR3-TACC3 fusion	Urothelial Cancer	FGFR3-TACC3 fusion	Urothelial Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR3 fusion	Cholangiocarcinoma	FGFR3 fusion	Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR1 fusion	Cholangiocarcinoma	FGFR1 fusion	Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 amplification	Gastric Cancer	FGFR2 amplification	Gastric Cancer	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3	Debio 1347 Resistant: C3 – Early Trials Debio 1347 Resistant : C3
FGFR2-INA fusion	Colon Cancer	FGFR2-INA fusion	Colon Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 fusion	Colon Cancer	FGFR2 fusion	Colon Cancer	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2-KIAA1217 fusion	Cholangiocarcinoma	FGFR2-KIAA1217 fusion	Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3	Debio 1347 Sensitive: C3 – Early Trials Debio 1347 Sensitive : C3
AR positive	Prostate Cancer	AR positive	Prostate Cancer	enzalutamide + Debio 1347 Sensitive: D – Preclinical enzalutamide + Debio 1347 Sensitive : D	enzalutamide + Debio 1347 Sensitive: D – Preclinical enzalutamide + Debio 1347 Sensitive : D
AR positive	Prostate Cancer	AR positive	Prostate Cancer	erdafitinib + Debio 1347 Sensitive: D – Preclinical erdafitinib + Debio 1347 Sensitive : D	erdafitinib + Debio 1347 Sensitive: D – Preclinical erdafitinib + Debio 1347 Sensitive : D